Published in Drug Metab Dispos on August 01, 2002
Systematic genetic and genomic analysis of cytochrome P450 enzyme activities in human liver. Genome Res (2010) 2.06
Colonization-induced host-gut microbial metabolic interaction. MBio (2011) 2.04
The pharmacological importance of cytochrome CYP3A4 in the palliation of symptoms: review and recommendations for avoiding adverse drug interactions. Support Care Cancer (2006) 1.57
CYP3A5 phenotype-genotype correlations in a British population. Br J Clin Pharmacol (2003) 1.47
Evidence of CYP3A allosterism in vivo: analysis of interaction between fluconazole and midazolam. Clin Pharmacol Ther (2011) 1.47
Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos (2012) 1.24
An integrated pharmacokinetics ontology and corpus for text mining. BMC Bioinformatics (2013) 1.17
Contributions of human enzymes in carcinogen metabolism. Chem Res Toxicol (2012) 1.11
Dynamic patterns of histone methylation are associated with ontogenic expression of the Cyp3a genes during mouse liver maturation. Mol Pharmacol (2009) 1.09
Pharmacogenomics of Cytochrome P450 3A4: Recent Progress Toward the "Missing Heritability" Problem. Front Genet (2013) 1.07
CYP3A5*3 and *6 single nucleotide polymorphisms in three distinct Asian populations. Eur J Clin Pharmacol (2003) 1.06
Changes to methadone clearance during pregnancy. Eur J Clin Pharmacol (2005) 1.03
Structural features of cytochromes P450 and ligands that affect drug metabolism as revealed by X-ray crystallography and NMR. Future Med Chem (2010) 0.99
Chronic hepatitis C: This and the new era of treatment. World J Hepatol (2016) 0.98
Gene expression in primate liver during viral hemorrhagic fever. Virol J (2009) 0.97
Midazolam metabolism in cytochrome P450 3A knockout mice can be attributed to up-regulated CYP2C enzymes. Mol Pharmacol (2007) 0.97
The structural basis for homotropic and heterotropic cooperativity of midazolam metabolism by human cytochrome P450 3A4. Biochemistry (2011) 0.95
Quantitative prediction of macrolide drug-drug interaction potential from in vitro studies using testosterone as the human cytochrome P4503A substrate. Eur J Clin Pharmacol (2006) 0.94
A Semi-Mechanistic Metabolism Model of CYP3A Substrates in Pregnancy: Predicting Changes in Midazolam and Nifedipine Pharmacokinetics. CPT Pharmacometrics Syst Pharmacol (2012) 0.92
Dynamically simulating the interaction of midazolam and the CYP3A4 inhibitor itraconazole using individual coupled whole-body physiologically-based pharmacokinetic (WB-PBPK) models. Theor Biol Med Model (2007) 0.92
Cytochrome P450 3A and their regulation. Naunyn Schmiedebergs Arch Pharmacol (2003) 0.90
Pharmacokinetics of midazolam in CYP3A4- and CYP3A5-genotyped subjects. Eur J Clin Pharmacol (2004) 0.88
New treatment strategies for hepatitis C infection. World J Hepatol (2015) 0.88
Nifedipine pharmacokinetics are influenced by CYP3A5 genotype when used as a preterm labor tocolytic. Am J Perinatol (2012) 0.87
Inhibition of CYP3A4 and CYP3A5 catalyzed metabolism of alprazolam and quinine by ketoconazole as racemate and four different enantiomers. Eur J Clin Pharmacol (2007) 0.85
The Making of a CYP3A Biomarker Panel for Guiding Drug Therapy. J Pers Med (2012) 0.83
Development of a Physiologically-Based Pharmacokinetic Model for Sirolimus: Predicting Bioavailability Based on Intestinal CYP3A Content. CPT Pharmacometrics Syst Pharmacol (2013) 0.83
Concurrent assessment of hepatic and intestinal cytochrome P450 3A activities using deuterated alfentanil. Clin Pharmacol Ther (2011) 0.83
Discordant associations between SLCO1B1 521T→C and plasma levels of ritonavir-boosted protease inhibitors in AIDS clinical trials group study A5146. Ther Drug Monit (2013) 0.82
Expression and regulation of human fetal-specific CYP3A7 in mice. Endocrinology (2012) 0.81
Effects of cytochrome P450 3A modulators ketoconazole and carbamazepine on quetiapine pharmacokinetics. Br J Clin Pharmacol (2006) 0.81
Metabolic capabilities of cytochrome P450 enzymes in Chinese liver microsomes compared with those in Caucasian liver microsomes. Br J Clin Pharmacol (2012) 0.80
Evaluation of CYP3A activity in humans using three different parameters based on endogenous cortisol metabolism. Acta Pharmacol Sin (2009) 0.80
Meconium Atazanavir Concentrations and Early Language Outcomes in HIV-Exposed Uninfected Infants With Prenatal Atazanavir Exposure. J Acquir Immune Defic Syndr (2015) 0.80
CYP3A5 polymorphism, amlodipine and hypertension. J Hum Hypertens (2013) 0.79
A new CYP3A5 variant, CYP3A5*11, is shown to be defective in nifedipine metabolism in a recombinant cDNA expression system. Drug Metab Dispos (2006) 0.79
Reduced methylprednisolone clearance causing prolonged pharmacodynamics in a healthy subject was not associated with CYP3A5*3 allele or a change in diet composition. J Clin Pharmacol (2006) 0.78
The impact of CYP3A5*3 polymorphism on sirolimus pharmacokinetics: insights from predictions with a physiologically-based pharmacokinetic model. Br J Clin Pharmacol (2015) 0.78
Limited contribution of CYP3A5 to the hepatic 6beta-hydroxylation of testosterone. Naunyn Schmiedebergs Arch Pharmacol (2004) 0.78
Effect of CYP3A5 expression on the inhibition of CYP3A-catalyzed drug metabolism: impact on modeling CYP3A-mediated drug-drug interactions. Drug Metab Dispos (2013) 0.78
Comparison of CYP3A4 and CYP3A5: the effects of cytochrome b5 and NADPH-cytochrome P450 reductase on testosterone hydroxylation activities. Drug Metab Pharmacokinet (2012) 0.77
Alprazolam as a probe for CYP3A using a single blood sample: pharmacokinetics of parent drug, and of alpha- and 4-hydroxy metabolites in healthy subjects. Eur J Clin Pharmacol (2005) 0.77
Worldwide distribution of cytochrome P450 alleles: A meta-analysis of population-scale sequencing projects. Clin Pharmacol Ther (2017) 0.77
Effect of CYP3A5*3 genotype on the pharmacokinetics and antiplatelet effect of clopidogrel in healthy subjects. Eur J Clin Pharmacol (2008) 0.76
Inter-individual variation in midazolam clearance in children. Arch Dis Child (2014) 0.76
Verification of a Maternal-Fetal Physiologically Based Pharmacokinetic Model for Passive Placental Permeability Drugs. Drug Metab Dispos (2017) 0.76
CYP3A7*1C allele is associated with reduced levels of 2-hydroxylation pathway oestrogen metabolites. Br J Cancer (2017) 0.75
Impact of genetic and nongenetic factors on interindividual variability in 4β-hydroxycholesterol concentration. Eur J Clin Pharmacol (2016) 0.75
In-vivo relation between plasma concentration of sorafenib and its safety in Chinese patients with metastatic renal cell carcinoma: a single-center clinical study. Oncotarget (2017) 0.75
Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1 deacetylase. EMBO J (2004) 11.00
Comparison of two methods to detect publication bias in meta-analysis. JAMA (2006) 7.34
Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ (2011) 6.80
Randomized trial of mediastinal lymph node sampling versus complete lymphadenectomy during pulmonary resection in the patient with N0 or N1 (less than hilar) non-small cell carcinoma: results of the American College of Surgery Oncology Group Z0030 Trial. J Thorac Cardiovasc Surg (2011) 5.14
Morbidity and mortality of major pulmonary resections in patients with early-stage lung cancer: initial results of the randomized, prospective ACOSOG Z0030 trial. Ann Thorac Surg (2006) 3.76
The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J Pharmacol Exp Ther (2003) 3.71
Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis (2005) 3.63
The PHD finger of the chromatin-associated protein ING2 functions as a nuclear phosphoinositide receptor. Cell (2003) 3.36
The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab Dispos (2003) 3.33
Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology (2004) 3.27
To RCT or not to RCT: deciding when 'more evidence is needed' for public health policy and practice. J Epidemiol Community Health (2011) 3.26
How vague is vague? A simulation study of the impact of the use of vague prior distributions in MCMC using WinBUGS. Stat Med (2005) 2.95
Contour-enhanced meta-analysis funnel plots help distinguish publication bias from other causes of asymmetry. J Clin Epidemiol (2008) 2.93
Video-assisted thoracic surgery versus open lobectomy for lung cancer: a secondary analysis of data from the American College of Surgeons Oncology Group Z0030 randomized clinical trial. J Thorac Cardiovasc Surg (2010) 2.31
Dap1/PGRMC1 binds and regulates cytochrome P450 enzymes. Cell Metab (2007) 2.30
Monitoring mortality rates in general practice after Shipman. BMJ (2003) 2.26
STS database risk models: predictors of mortality and major morbidity for lung cancer resection. Ann Thorac Surg (2010) 2.25
A systematic review of systematic reviews and meta-analyses of animal experiments with guidelines for reporting. J Environ Sci Health B (2006) 2.23
Pathologic lymph node ratio is a predictor of survival in esophageal cancer. Ann Thorac Surg (2012) 2.20
Predicted risk of mortality models: surgeons need to understand limitations of the University HealthSystem Consortium models. J Am Coll Surg (2009) 2.10
Ten-year experience on 644 patients undergoing single-port (uniportal) video-assisted thoracoscopic surgery. Ann Thorac Surg (2013) 2.01
The conduct of in vitro and in vivo drug-drug interaction studies: a PhRMA perspective. J Clin Pharmacol (2003) 1.97
Hepatic CYP2B6 expression: gender and ethnic differences and relationship to CYP2B6 genotype and CAR (constitutive androstane receptor) expression. J Pharmacol Exp Ther (2003) 1.94
Special treatment issues in lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest (2007) 1.94
Occult metastases in lymph nodes predict survival in resectable non-small-cell lung cancer: report of the ACOSOG Z0040 trial. J Clin Oncol (2011) 1.93
Factors affecting uptake of childhood immunisation: a Bayesian synthesis of qualitative and quantitative evidence. Lancet (2002) 1.91
Ischemia-reperfusion injury after lung transplantation increases risk of late bronchiolitis obliterans syndrome. Ann Thorac Surg (2002) 1.91
Finding qualitative research: an evaluation of search strategies. BMC Med Res Methodol (2004) 1.89
Mechanism-based inactivation of CYP3A by HIV protease inhibitors. J Pharmacol Exp Ther (2004) 1.89
Performance of the trim and fill method in the presence of publication bias and between-study heterogeneity. Stat Med (2007) 1.83
Ineffectiveness of histone deacetylase inhibitors to induce apoptosis involves the transcriptional activation of NF-kappa B through the Akt pathway. J Biol Chem (2003) 1.73
A randomized controlled trial of adaptive ventilation for Cheyne-Stokes breathing in heart failure. Am J Respir Crit Care Med (2003) 1.72
Functional interdependence at the chromatin level between the MKK6/p38 and IGF1/PI3K/AKT pathways during muscle differentiation. Mol Cell (2007) 1.70
Primary payer status affects mortality for major surgical operations. Ann Surg (2010) 1.69
Breast cancer metastasis suppressor 1 functions as a corepressor by enhancing histone deacetylase 1-mediated deacetylation of RelA/p65 and promoting apoptosis. Mol Cell Biol (2006) 1.68
Hepatic cytochrome P450 2E1 activity in nondiabetic patients with nonalcoholic steatohepatitis. Hepatology (2003) 1.65
The impact of the lung allocation score on short-term transplantation outcomes: a multicenter study. J Thorac Cardiovasc Surg (2007) 1.65
Comparative analysis of showering protocols for mass-casualty decontamination. Prehosp Disaster Med (2010) 1.62
Methodology and reporting of systematic reviews and meta-analyses of observational studies in psychiatric epidemiology: systematic review. Br J Psychiatry (2012) 1.60
Thirty- and ninety-day outcomes after sublobar resection with and without brachytherapy for non-small cell lung cancer: results from a multicenter phase III study. J Thorac Cardiovasc Surg (2011) 1.59
Literature based drug interaction prediction with clinical assessment using electronic medical records: novel myopathy associated drug interactions. PLoS Comput Biol (2012) 1.58
High dose melphalan in the treatment of advanced neuroblastoma: results of a randomised trial (ENSG-1) by the European Neuroblastoma Study Group. Pediatr Blood Cancer (2005) 1.55
Clinical pharmacokinetics of atomoxetine. Clin Pharmacokinet (2005) 1.55
Differences in reported esophageal cancer resection outcomes between national clinical and administrative databases. J Thorac Cardiovasc Surg (2012) 1.54
Airflows around oxygen masks: A potential source of infection? Chest (2006) 1.53
Drug interactions with herbal products and grapefruit juice: a conference report. Clin Pharmacol Ther (2004) 1.51
EUS-FNA as the initial diagnostic modality in centrally located primary lung cancers. J Clin Gastroenterol (2007) 1.51
Efavirenz primary and secondary metabolism in vitro and in vivo: identification of novel metabolic pathways and cytochrome P450 2A6 as the principal catalyst of efavirenz 7-hydroxylation. Drug Metab Dispos (2010) 1.50
A systematic review of molecular and biological tumor markers in neuroblastoma. Clin Cancer Res (2004) 1.47
Intraoperative factors and the risk of respiratory complications after pneumonectomy. Ann Thorac Surg (2011) 1.45
Visualization of PtdIns3P dynamics in living plant cells. Plant J (2006) 1.44
The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. Clin Pharmacol Ther (2004) 1.44
A novel technique for localization and excisional biopsy of small or ill-defined pulmonary lesions. Ann Thorac Surg (2004) 1.43
Effects of a novel mGlu₂/₃ receptor agonist prodrug, LY2140023 monohydrate, on central monoamine turnover as determined in human and rat cerebrospinal fluid. Psychopharmacology (Berl) (2011) 1.42
Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans. J Clin Pharmacol (2009) 1.41
Exhaled air dispersion distances during noninvasive ventilation via different Respironics face masks. Chest (2009) 1.41
Flexible parametric models for relative survival, with application in coronary heart disease. Stat Med (2007) 1.40
Evidence synthesis as the key to more coherent and efficient research. BMC Med Res Methodol (2009) 1.39
The use of systematic reviews when designing studies. Clin Trials (2005) 1.39
Drug-induced QT prolongation in cirrhotic patients with transjugular intrahepatic portosystemic shunt. J Clin Gastroenterol (2011) 1.38
GLM-beamformer method demonstrates stationary field, alpha ERD and gamma ERS co-localisation with fMRI BOLD response in visual cortex. Neuroimage (2005) 1.35
Evidence-based sample size calculations based upon updated meta-analysis. Stat Med (2007) 1.35
Metabolic costs of foraging and the management of O2 and CO2 stores in Steller sea lions. J Exp Biol (2008) 1.34
Genome-wide expression profiling reveals genes associated with amphotericin B and fluconazole resistance in experimentally induced antifungal resistant isolates of Candida albicans. J Antimicrob Chemother (2004) 1.33
Suberoylanilide hydroxamic acid induces Akt-mediated phosphorylation of p300, which promotes acetylation and transcriptional activation of RelA/p65. J Biol Chem (2006) 1.30
Effect of St John's wort on the pharmacokinetics of fexofenadine. Clin Pharmacol Ther (2002) 1.28
Stochastic prediction of CYP3A-mediated inhibition of midazolam clearance by ketoconazole. Drug Metab Dispos (2006) 1.27
Selective metabolism of vincristine in vitro by CYP3A5. Drug Metab Dispos (2006) 1.26
Tumor Spread through Air Spaces is an Important Pattern of Invasion and Impacts the Frequency and Location of Recurrences after Limited Resection for Small Stage I Lung Adenocarcinomas. J Thorac Oncol (2015) 1.24
Existing general population models inaccurately predict lung cancer risk in patients referred for surgical evaluation. Ann Thorac Surg (2011) 1.23
Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes P450. Drug Metab Dispos (2006) 1.20
Leiomyoma presenting as a massive calcified circumferential esophageal mass. Ann Thorac Surg (2013) 1.19
Effect of race on vincristine-associated neurotoxicity in pediatric acute lymphoblastic leukemia patients. Pediatr Blood Cancer (2008) 1.18
Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition. J Clin Invest (2016) 1.18
Tumor recurrence after complete resection for non-small cell lung cancer. Ann Thorac Surg (2012) 1.18
Relationship among histologic, radiologic, and biochemical assessments of hepatic steatosis: a study of human liver samples. J Clin Gastroenterol (2007) 1.18
Increased risk of vincristine neurotoxicity associated with low CYP3A5 expression genotype in children with acute lymphoblastic leukemia. Pediatr Blood Cancer (2010) 1.18
In vivo DPP-4 inhibition to enhance engraftment of single-unit cord blood transplants in adults with hematological malignancies. Stem Cells Dev (2013) 1.17
Quantification of tamoxifen and three metabolites in plasma by high-performance liquid chromatography with fluorescence detection: application to a clinical trial. J Chromatogr B Analyt Technol Biomed Life Sci (2003) 1.17
Identification of the human cytochromes P450 responsible for atomoxetine metabolism. Drug Metab Dispos (2002) 1.16
T cell activation in vivo targets diacylglycerol kinase alpha to the membrane: a novel mechanism for Ras attenuation. J Immunol (2003) 1.15
PTEN blocks tumor necrosis factor-induced NF-kappa B-dependent transcription by inhibiting the transactivation potential of the p65 subunit. J Biol Chem (2002) 1.15
Exercise warms adult leatherback turtles. Comp Biochem Physiol A Mol Integr Physiol (2006) 1.15
Involvement of Toll-like receptor 4 in acetaminophen hepatotoxicity. Am J Physiol Gastrointest Liver Physiol (2006) 1.14
Noninvasive positive-pressure ventilation: An experimental model to assess air and particle dispersion. Chest (2006) 1.13
The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity. Clin Pharmacol Ther (2003) 1.13
Proteasome inhibition sensitizes non-small cell lung cancer to histone deacetylase inhibitor-induced apoptosis through the generation of reactive oxygen species. J Thorac Cardiovasc Surg (2004) 1.13
Diabetes mellitus increases the in vivo activity of cytochrome P450 2E1 in humans. Br J Clin Pharmacol (2003) 1.11
Physiologically based pharmacokinetic model of mechanism-based inhibition of CYP3A by clarithromycin. Drug Metab Dispos (2009) 1.11
The interaction between St John's wort and an oral contraceptive. Clin Pharmacol Ther (2003) 1.10
Three-dimensional quantitative structure-activity relationship for inhibition of human ether-a-go-go-related gene potassium channel. J Pharmacol Exp Ther (2002) 1.10
Size matters: a comparison of T1 and T2 peripheral non-small-cell lung cancers treated with stereotactic body radiation therapy (SBRT). J Thorac Cardiovasc Surg (2010) 1.09